Skip to content

Science
Investor
About
Learn
Contact

Science
Investor
About
Learn
Contact

Investor Alerts

Investor

News Releases

These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.

Year Keywords

Advanced Search

Search

Search Headlines Only

From

To

Asset Types

Photos Video Audio Documents Events Standard

Jan 8, 2021

InMed Announces Results of Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
Jan 5, 2021

InMed to Participate at Virtual Conferences in January 2021
Dec 3, 2020

InMed Licenses MiDROPS® Delivery Technology from EyeCRO for the Delivery of Therapeutic Cannabinoids
Nov 25, 2020

InMed Announces Results of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
Nov 24, 2020

InMed Announces Election of Directors
Nov 18, 2020

InMed Pharmaceuticals and BayMedica Announce Collaboration for Manufacturing and Testing of Novel Cannabinoid Therapeutics
Nov 16, 2020

InMed Pharmaceuticals Announces the Closing of US$8 Million Public Offering
Nov 13, 2020

InMed Pharmaceuticals Reports First Quarter Fiscal 2021 IFRS Financial Results
Nov 12, 2020

InMed Announces Pricing of US$8M Public Offering and Listing on the Nasdaq Capital Market Under the Symbol "INM"
Nov 5, 2020

InMed Reschedules Reporting of First Quarter Financial Results and Business Update to November 13, 2020
Nov 4, 2020

InMed Pharmaceuticals to Report First Quarter Fiscal 2021 Financial Results and Business Update on November 6, 2020
Sep 24, 2020

InMed Announces Completion of Subject Treatments in Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
Sep 22, 2020

InMed Pharmaceuticals Announces Additional IntegraSyn™ Patent Filing
Sep 8, 2020

InMed Pharmaceuticals Reports Full Year Fiscal 2020 Financial Results and Provides Business Update
Sep 2, 2020

InMed Pharmaceuticals to Report Full Year Fiscal 2020 Financial Results and Business Update on September 8, 2020
Jul 7, 2020

InMed Announces Dosing Initiation in 2nd Phase 1 trial with INM-755
Jun 30, 2020

InMed Announces Completion of Share Consolidation
Jun 24, 2020

InMed Introduces IntegraSyn™: An Integrated Cannabinoid Manufacturing System
Jun 19, 2020

InMed Announces Filing of Registration Statement in Connection with United States Offering, Application to Seek Nasdaq Listing and Planned Share Consolidation
May 27, 2020

InMed Releases CBN Preclinical Results in Glaucoma
May 19, 2020

InMed Pharmaceuticals Continues to Strengthen Biosynthesis Patent Family
May 14, 2020

InMed Pharmaceuticals Reports Third Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update
May 12, 2020

InMed Files PCT Patent Application for Neuroprotection in Glaucoma
May 8, 2020

Notice of Telephone Scam Impersonating InMed
May 8, 2020

InMed Pharmaceuticals to Report Third Quarter Fiscal 2020 Financial Results and Business Update on May 14, 2020

Show 5 10 25 50 100 per page

«
1
2
3
4
5
6
7
»

Investor Alerts

Sign up for investor alerts!

Information Request

Send us a request for information

#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Science

INM-755 for Epidermolysis Bullosa
INM-088 for Glaucoma
INM-405 for Orofacial Pain
IntegraSyn™ Cannabinoid Manufacturing
InMed’s Research of Rare Cannabinoids

Investor

News Releases
Latest Presentation
Letter to Shareholders
SEDAR^® Filings
Financial Reports

About

Management
Board of Directors
Scientific Advisory Board
Corporate Governance
Careers
Frequently Asked Questions

Learn

What is Cannabinol (CBN)?
What is Epidermolysis Bullosa (EB)?
What is Glaucoma?
Cannabinoids for Glaucoma
Cannabinoid Science
Articles and Videos

© Copyright 2020 InMed Pharmaceuticals Inc.

Privacy Policy
Terms of Use
Legal Disclaimer

Find Us On: